ACT Capital Partners, L.P.’s Krystal Biotech KRYS Stock Holding History

ACT Capital Partners, L.P.’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14M	Buy	+42,000	New	+$14.5M	9.07%	2

Other funds holding KRYS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

ACT Capital Partners, L.P.'s KRYS Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Krystal Biotech (KRYS) in Q3 2026: 42,000 shares worth $14M. The stake represents 9.07% of the portfolio and ranks #2 among its holdings.

195 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

ACT Capital Partners, L.P. held 42,000 shares of Krystal Biotech worth $14M as of Q3 2026.
Krystal Biotech was a new ACT Capital Partners, L.P. position in Q3 2026.
Krystal Biotech made up 9.07% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #2 holding.
195 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.